About Beta-1,4-galactosyltransferase 1
Beta-1,4-galactosyltransferase 1 (B4GALT1) is a protein
from Homo sapiens identified by UniProt accession
P15291, 398 residues long.
MolForge cross-references it against 0 known binders and
233 disease associations.
Target properties
| Protein name | Beta-1,4-galactosyltransferase 1 |
| UniProt accession | P15291 |
| Gene | B4GALT1 |
| Organism | Homo sapiens |
| Length | 398 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (233)
Diseases linked to this target (Open Targets).
- B4GALT1-congenital disorder of glycosylation · score 0.75
- neurodegenerative disease · score 0.55
- congenital disorder of glycosylation type II · score 0.53
- serum IgG glycosylation measurement · score 0.51
- urate measurement · score 0.49
- aspartate aminotransferase measurement · score 0.49
- congenital disorder of glycosylation · score 0.46
- combined low LDL and fibrinogen · score 0.45
- hemoglobin measurement · score 0.43
- erythrocyte count · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P15291-F1 | alphafold | PREDICTED | 83.73 | — |
Amino-acid sequence (398 residues)
MRLREPLLSG SAAMPGASLQ RACRLLVAVC ALHLGVTLVY YLAGRDLSRL PQLVGVSTPL QGGSNSAAAI GQSSGELRTG GARPPPPLGA SSQPRPGGDS SPVVDSGPGP ASNLTSVPVP HTTALSLPAC PEESPLLVGP MLIEFNMPVD LELVAKQNPN VKMGGRYAPR DCVSPHKVAI IIPFRNRQEH LKYWLYYLHP VLQRQQLDYG IYVINQAGDT IFNRAKLLNV GFQEALKDYD YTCFVFSDVD LIPMNDHNAY RCFSQPRHIS VAMDKFGFSL PYVQYFGGVS ALSKQQFLTI NGFPNNYWGW GGEDDDIFNR LVFRGMSISR PNAVVGRCRM IRHSRDKKNE PNPQRFDRIA HTKETMLSDG LNSLTYQVLD VQRYPLYTQI TVDIGTPS
Explore Beta-1,4-galactosyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets